Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) EBITDA Margin (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed EBITDA Margin for 6 consecutive years, with 2344700.0% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 59557273.0% to 2344700.0% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 762491.67% through Dec 2025, down 20083757.0% year-over-year, with the annual reading at 762491.67% for FY2025, 20083757.0% down from the prior year.
  • EBITDA Margin hit 2344700.0% in Q4 2025 for Lyell Immunopharma, down from 258013.33% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 12.4% in Q4 2022 to a low of 2396633.33% in Q3 2022.
  • Historically, EBITDA Margin has averaged 574600.1% across 5 years, with a median of 214847.04% in 2023.
  • Biggest five-year swings in EBITDA Margin: plummeted -239485428bps in 2022 and later soared 219801333bps in 2023.
  • Year by year, EBITDA Margin stood at 3021.4% in 2021, then skyrocketed by 100bps to 12.4% in 2022, then crashed by -3215894bps to 398792.31% in 2023, then crashed by -339bps to 1749127.27% in 2024, then crashed by -34bps to 2344700.0% in 2025.
  • Business Quant data shows EBITDA Margin for LYEL at 2344700.0% in Q4 2025, 258013.33% in Q3 2025, and 534812.5% in Q2 2025.